Sangamo Biosciences (SGMO) Announces ZFN-Mediated Genome Editing Program for Hemoglobinopathie Will Transfer to Bioverativ (BIIB)

November 30, 2016 7:09 AM EST

Get inside Wall Street with StreetInsider Premium. Claim your 2-week free trial here.

Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced that its collaborative zinc finger nuclease (ZFN)-mediated genome editing program for hemoglobinopathies will transfer to Bioverativ.

"Our collaboration with Biogen has been very successful, and we are delighted that these programs will be transitioning to Bioverativ," said Sandy Macrae, M.B., Ch.B., Ph.D., Sangamo's president and chief executive officer. "We believe that the incorporation of these programs into the Bioverativ pipeline will further progress the development of these potentially life-changing therapeutics."

"We are excited to add Sangamo's ZFN genome editing programs for sickle cell disease and beta-thalassemia to our pipeline, which will be focused on areas of significant unmet medical need in rare blood disorders," said John G. Cox, chief executive officer of Bioverativ, and Biogen's former executive vice president, pharmaceutical operations & technology. "We look forward to working with Sangamo to advance these important programs."

In 2014, Sangamo and Biogen entered into an exclusive worldwide research, development and commercialization collaboration and license agreement under which both companies agreed to develop and commercialize therapeutic genome editing products for the potential treatment of two inherited blood disorders, sickle cell disease and beta-thalassemia. Bioverativ, the planned spin-off of Biogen's hemophilia business, is on track to launch as an independent, publicly-traded biotechnology company in early 2017.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Corporate News, Management Comments, Spinoffs

Add Your Comment